From: Mechanistic insight into the impact of nanomaterials on asthma and allergic airway disease
Nanomaterial Properties | Model Characteristics | Disease Related Endpoints | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Material (coating) | Size (nm) | Surface area (m 2 /g) | Agg size (nm) | Species (Strain - Gender) | Allergen (Route) | Particle (Route) | Dose | AHR (LF test) | IgE | Eos | Neu | Lym | MΦ | Total Cells | Pathophysiological Indicators | GCH-MS | Reference |
Ag | 6 | 0.11 | - | Mice (BALBc –f) | OVA (IP) | A | 40mg/kg x5d | ↓ (Penh) | - | ↓ | nc | - | nc | ↓ | ↓ (IL-4 IL-5, IL-13, VEGF) | ↓ MUC5AC | [112] |
Ag | 6 | - | - | Mice (C57BL/6 –f) | OVA (IP) | A | 40mg/kg x5d | ↓ (Penh) | - | ↓ | nc | ↓ | nc | ↓ | ↓ (IL-4 IL-5, IL-13, NFkB) | - | [111] |
Ag | 33 | - | - | Mice (BALB/c –f) | OVA (IP) | A | 3.3mg/m3 x6h/d x7d | - | ↑ | - | - | - | - | - | - | - | [274] |
Ag | 33 | 0.016 | - | Mice (BALB/c –f) | OVA (Int N) | A | 3.3mg/m3 x6h x7d | nc (Penh) | nc | nc | nc | nc | nc | nc | nc (IL-13) - | - | [116] |
Au | 40 | - | - | Mice (BALB/c –m) | TDI (dermal) | OA | 0.8 mg/kg | ↑ (Resist) | nc | nc | ↑ | - | ↑ | ↑ | ↓ (TNF-α, IL-6) nc (MIP-2, MCP-1) | - | [63] |
Au | 6.3 | - | - | Mice (A/J –m) | OVA (IP) | Int N | 60μg/Kg x2 | ↓ (Resist) | - | ↓ | - | - | - | - | ↓ (IL-4, IL-13, CCL11, CCL24) | ↓ PAS | [117] |
Au | 6.3 | - | - | Mice (Swiss Webster –m) | OVA (IP) | Int N | 60μg/Kg x2 | - | - | ↓ | ↓ | - | ↓ | ↓ | ↓ (IL-5, Il-1β, IL-6, ROS) | - | [117] |
TiO2 | 22 | - | 272 | Mice (BALB/c –m) | TDI (dermal) | OA | 0.8 mg/kg | nc (Resist) | nc | nc | ↑ | - | ↑ | ↑ | nc (TNF-α, IL-6, MIP-2, MCP-1) | - | [63] |
CuO | 46.67 | - | 375.8 | Mice 0(BALB/c –f) | OVA (IP) | Int N | 100μg/kg x3 | ↑ (Penh) | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ (ROS, IL-5, IL-6, TNF-α, IL-13, IL-4 | ↑ MUC5AC | [64] |
C | 20 | 442 | 344-5720 | Mice (C57BL/6 –f) | OVA (IP) | PA | 10mg/kg | - | - | - | ↑ | - | nc | ↑ | - | - | [60] |
C | 34.8 | - | - | Mice (BALB/c) | OVA (A) | A | 526μg/m3 x24h | ↑ (Penh) | - | ↑ | - | ↑ | ↑ | - | ↑(IL-13), ↓(IL-5), nc (IL-4) | ↑ PAS | [61] |
C | 53.2 | - | - | Mice (BALB/c –f) | OVA (IP) | A | 504μg/m3 (24h) | ↑ (Penh) | - | ↑ | - | ↑ | nc | ↑ | ↑ (IL-5, IL-13) | - | [110] |
C | 35.2 | - | - | Dog (Beagle) | Ragweed (IP) | A | 232.3μg/m3 | nc (Resist) | nc | nc | ↑ | nc | nc | nc | - | - | [58] |
C | 7 | - | - | Mice (BALB/c –f) | OVA (IP) | A | 507μg/m3 x24h | - | - | nc | ↑* | - | nc | - | ↑ (LTB4, PGE2), nc (8-isoprostane) | - | [59] |
C | 7 | - | - | Mice (BALB/c) | OVA (IP) | A | 507μg/m3 x24h | - | - | - | - | - | - | - | ↑ (TNF-α), nc (CC16) | ↑ PAS | [62] |
α-Fe2O3 | 30 | 28.98 | 950-2000 | Mice (BALB/c –f) | OVA (IP) | Int T | 5mg/kg | - | nc | ↓ | nc | ↓ | ↓ | ↓ | nc (TNF-α, Il-1β, IL6) | - | [275] |
FeO2 | 43 | 41.95 | 200 | Mice (BALB/c –m) | OVA (IP) | Int T | 1.1mg/kg x3 | - | - | - | - | ↑ | - | ↑ | ↑ (IFN-γ), nc (IL-4) | - | [93] |
GO | D 0.61, L 0.02-2μm | - | - | Mice (BALB/c –f) | OVA (IP) | PA | 2.2mg/kg x4 | nc (Penh) | nc | nc | ↑ | ↓ | nc | - | nc (IL-4, IL-5, IL-13) | - | [65] |
SiO2 | 14 | - | - | Mice (BALB/c –f) | OVA (IP) | Int T | 2.7mg/kg | nc (Resist) | - | ↑ | ↑ | ↑ | ↓ | - | ↑ (IL-13, MCP-1, MIP-1, Tarc); nc (IL-4, INF-γ, TNF-α, KC) | ↑ MUC5AC PAS | [66] |
SiO2 (PEG) | 14 | - | - | Mice (BALB/c –f) | OVA (IP) | Int T | 2.7mg/kg | ↑ (Resist) | - | ↑ | ↑ | ↑ | ↓ | - | ↑ (IL-4, IL-13, MCP-1, MIP-1, Tarc, KC), nc (INF-γ, TNF-α) | ↑ MUC5AC PAS | [66] |
SiO2 (PO4) | 14 | - | - | Mice (BALB/c –f) | OVA (IP) | Int T | 2.7mg/kg | nc (Resist) | - | nc | nc | nc | nc | - | ↑ (MIP-1); nc (IL-13, IL-4, INF-γ, TNF-α, MCP-1, Tarc, KC) | nc MUC5AC PAS | [66] |
SiO2 (Amino) | 15 | - | - | Mice (BALB/c –f) | OVA (IP) | Int T | 2.7mg/kg | nc (Resist) | - | nc | nc | nc | ↑ | - | ↑ (IL-13, IL-4); ↓ (Tarc); nc (INF-γ, TNFα, MCP1, KC) | nc MUC5AC PAS | [66] |
SiO2 | 100 | 12.7 | - | Mice (BALB/c –f) | OVA (IP) | Int N | 11 mg/kg x3 | nc (Resist) | nc | nc | nc | nc | ↑ | ↑ | nc (IL-5, IL-13, IL-1β, INF-γ) | nc PAS | [276] |
SiO2 (Meso) | 100 | 70.6 |  | Mice (BALB/c –f) | OVA (IP) | Int N | 11 mg/kg x3 | nc (Resist) | nc | nc | nc | nc | ↑ | nc | nc (IL-5, IL-13, IL-1β, INF-γ) | nc PAS | [276] |
SiO2 (PEG) | 100 | 12.7 | - | Mice (BALB/c –f) | OVA (IP) | Int N | 11 mg/kg x3 | nc (Resist) | nc | nc | nc | nc | nc | nc | nc (IL-5, IL-13, IL-1β, INF-γ) | nc PAS | [276] |
TiO2 | 5 | - | 168 | Rat (BN –m) | OVA (IP) | A | 9.4mg/m3 x6h | - | - | ↓ | nc | ↓ | ↓ | ↓ | ↓ (MCP-1, IL-4, IL-6, INF-γ) | ↓ PAS | [118] |
TiO2 | 21 | - | 4200 | Rat (BN –m) | OVA (In) | A | 159 μg, deposited | nc (Resist) | nc | ↓ | nc | nc | nc | ↓ | - | - | [119] |
TiO2 | 21 | - | 4200 | Rat (DA-m) | OVA (In) | A | 168 μg, deposited | nc (Resist) | nc | ↓ | ↑ | ↑ | nc | nc | - | - | [119] |
TiO2 | 21 | - | 1.5 μm | Mice (BALB/c –f) | OVA (IP) | A | 193 μg, deposited | ↓ (Resist) | nc | ↓ | ↑ | ↓ | nc | ↓ | ↓ (IL-4, IL-13, IL-5,IL-6, INF-γ) | - | [120] |
TiO2 | 21 | - | 1.5 μm | Mice (BALB/c –f) | OVA (IP) | A | 32 μg, deposited | ↑ (Resist) | - | ↑ | ↑ | ↑ | ↑ | ↑ | nc (IL-4, IL-13, IL-5,IL-6, INF-γ) | - | [120] |
TiO2 | 4-8 | 130 | 244 | Mice (BALB/c) | OVA (IP) | Int N | 5.5 mg/kg x4 | nc (Resist) | - | - | - | - | - | - | - | - | [273] |
MWCNT | D – 9.5, L– 1.5μm | 250-300 | - | Rats (BN –f) | TMA (dermal) | A | 22mg/m3 x5h x7d | - | nc | nc | nc | ↓ | nc | nc | - | - | [68] |
MWCNT | D - 20–30, L-5-10μm | - | 324 | Mice (C57BL/6) | HDM (Int N) | O | 2 mg/kg | - | nc | nc | ↑ | nc | ↓ | ↑ | nc (IL-1β, IL-13, IL-4, IL-5 CCL20) ↑(CCL2, CXCL1/2) | - | [71] |
MWCNT | D 30–50 L 0.3-50μm | 109.29 | >2 μm | Mice (C57BL/6J) | OVA (IP) | OA | 4mg/kg | - | nc | ↓* | nc | nc | ↓ | - | nc (IL-13, IL-5,, IL-17α) ↓(TGF-β1) | nc PAS | [70] |
MWCNT | D 30–50 L 0.3-50μm | 109.29 | - | Mice (C57BL/6 –) | OVA (IP) | A | 100mg/m3 | - | - | nc | nc | nc | nc | - | nc (IL-13) ↑ (IL-5, TGF-β1) | - | [67] |
MWCNT | D 10–30 L 0.3-56μm | - | - | Mice (WT –m) | OVA (IP) | OA | 4mg/kg | - | - | nc | nc | nc | nc | nc | nc (IL-13, IL-1β, TGF-β1, TNF –α, IL-10) | nc PAS | [69] |